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Abstract
Background: Little is known about risk factors for severe outcomes in patients infected with H5N1 and no systematic review
has been conducted. Understanding risk factors is an important step for prioritizing prophylaxis or treatment in the event of
a pandemic.
Objectives: To systematically evaluate risk factors for severe outcomes in patients with avian influenza H5N1 infection.
Data sources: MEDLINE, EMBASE, CINAHL, GlobalHealth, and CENTRAL through March 2011
Eligibility criteria for selecting studies: Observational studies of any design published in English, French, Spanish, German
or Korean that reported on risk factor-outcome combinations of interest in participants with confirmed H5N1 infections.
Outcomes considered included death, ventilator support, hospital and ICU admission, pneumonia, and composite
outcomes.
Study appraisal: Risk of bias was assessed using the Newcastle-Ottawa scale (NOS).
Results:We identified 20 studies reporting on 999 patients infected with H5N1. The majority of studies (n = 14, 70%) were at
intermediate risk of bias, i.e. 4–6 points on the NOS. Females were at increased risk of death (OR 1.75, 95% CI 1.27–2.44),
while young age, in particular ,5 years of age (OR 0.44, 95% CI 0.25–0.79 for death), was protective. Data on traditional risk
factors was scarce and requires further studies. Another major limitation in the published literature was lack of adjustment
for confounders.
Interpretation: Females were at increased risk for complications following H5N1 infection while young age protected
against severe outcomes. Research on traditional risk factors was limited and is required.
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Introduction
Outbreaks of highly pathogenic avian influenza H5N1 infec-
tions in poultry were first reported from Guangdong, China in
1996 [1]. Since a cluster in Hong Kong in 1997, transmission to
humans has been intermittently reported and, as of April 2013, a
total of 628 confirmed cases with 374 deaths of H5N1 infected
patients (59.6% case fatality rate) have been reported to the World
Health Organization (WHO) from 15 countries [2].
Understanding risk factors for severe outcomes is an important
step in order to prioritize prophylaxis or treatment in the event of
a pandemic. As part of a systematic review sponsored by the
WHO, we aimed to identify risk factors for severe outcomes or
complications of influenza infections. We report our findings
specific to highly pathogenic avian influenza H5N1.
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Materials and Methods
The methods were reported in detail previously [3]. Briefly, we
included studies reporting on at least one risk factor-outcome
combination of interest irrespective of the study design. Only
single-case reports were excluded, but case series reporting on
patients with and without a specific outcome for a particular risk
factor of interest were included. Articles based on secondary
analyses of previously published data and review articles were not
eligible. Outcomes of interest included community-acquired
pneumonia, mortality, hospitalization, intensive care unit (ICU)
admission, need for ventilator support, and composite outcomes.
Studies in English, French, German, Spanish, and Korean were
included.
We searched MEDLINE, EMBASE, CINAHL, Global Health,
and the Cochrane Central Register of Controlled Trials (CEN-
TRAL) up to March 29 of 2011 and reference lists of identified
articles and review articles. Screening and data abstraction were
conducted independently and in duplicate by pairs of reviewers
using piloted and standardized forms. Two reviewers assessed the
risk of bias independently using the Newcastle-Ottawa scale (NOS)
[4].
A random-effects model was used to calculate summary
estimates using Review Manager 5.0 (Cochrane Collaboration)
[5]. Risk estimates are reported as odds ratio (OR) with 95%
confidence intervals (CI). If there was a potential overlap in study
populations across studies in a meta-analysis, studies were
excluded in a sensitivity analysis in order to minimize any effect
of such overlap. The I2 statistics was used to evaluate heterogeneity
[6]. Two a priori defined subgroup analysis based on the place of
enrollment (community versus hospital versus ICU population)
and risk of bias in included studies were conducted in the presence
of significant heterogeneity defined by I2.60% [7]. Funnel plots
were visually interpreted to assess publication bias but no formal
statistical tests were conducted due to the small number of studies
for the vast majority of risk factor-outcome combinations.
The World Health Organization (WHO) funded the study. The
protocol was reviewed by the WHO and the WHO’s suggestion
were incorporated into the protocol.
Results
Out of 47,874 titles and abstracts screened, 20 studies
[8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27] that
included 999 patients reported risk factors for severe outcomes for
Figure 1. Flow diagram of included and excluded studies.
doi:10.1371/journal.pone.0089697.g001
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Figure 2. Forest plot comparing mortality in females as compared to males.
doi:10.1371/journal.pone.0089697.g002
Table 1. Summary estimates of risk-factor–outcome comparisons during H5N1 Avian influenza with odds ratio (95% confidence
interval), I2, and number of included studies (n); where applicable, sensitivity analysis in italic fonts.
Pneumonia ICU admission Ventilator support All-cause mortality
Female sex 3.03 (0.91–10.00), 0%, n = 4 3.70 (0.33–50.00), n/a, n = 1 2.94 (0.43–20.00), 0%, n = 3 1.75*(1.27–2.44), 0%, n = 17
5.00 (0.91–33.33), 0%, n = 2 2.27*(1.12–4.55), 50%, n = 4
Elderly vs. non elderly adults n/a n/a n/a 1.04 (0.12–9.08), 0%, n = 2
Paediatric vs. adults 0.16*(0.03–0.86), 0%, n = 3 0.50 (0.02–12.90), n/a, n = 1 0.62 (0.09–4.45), 0%, n = 3 0.72 (0.34–1.51), 71%, n = 14
0.12 (0.01–1.03), 0%, n = 2 0.21 (0.03–1.41), 87%, n = 4
Paediatric vs. 0.12 (0.01–1.03), 0%, n = 2 0.50 (0.02–12.90), n/a, n = 1 0.93 (0.10–8.27), 0%, n = 2 0.48 (0.13–1.79), 73%, n = 6
non-elderly adults 0.25 (0.04–1.55), 87%, n = 3
,5 y in paediatric 0.27 (0.01–7.59), 50%, n = 2 n/a 0.11 (0.00–3.35), n/a, n = 1 0.44*(0.25–0.79), 0%, n = 7
population 0.06 (0.00–1.23),n/a, n = 1 0.42*(0.18–0.97), 0%, n = 2
,2 y in paediatric population 0.71 (0.02–22.34), n/a, n = 1 n/a n/a 1.13 (0.03–37.44), n/a, n = 1
Any risk factor or 1.71 (0.35–8.36), 0%, n = 2 0.60 (0.05–6.79), n/a, n = 1 n/a 1.04 (0.20–5.35), 9%, n = 2
co-morbidity 1.43 (0.18–11.1),n/a, n = 1
Smoking 9.00 (0.30–271.65), n/a, n = 1 5.00 (0.15–166.59), n/a, n = 1 0.58 (0.06–5.55), 0%, n = 2 0.56 (0.05–5.55), 0%, n = 2
*: statistical significance, ICU: admission to intensive care unit, y: years; sensitivity analysis in italic: exclusion of studies with a potential overlap in patient population.
doi:10.1371/journal.pone.0089697.t001
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H5N1 avian influenza (Figure 1). All studies were cohort studies
and published in English between 1998 and 2010. Evidence of
H5N1 influenza infection was by laboratory confirmation in all
studies. Only two studies reported on cases outside of Asia.
As assessed by the Newcastle-Ottawa scale, the majority of
studies were at intermediate risk of bias (i.e. 4–6 points; n = 14,
70%) while 4 (20%) were at highest risk of bias (i.e. 3 or less points)
and 2 (10%) at lowest risk of bias (i.e. 7–9 points). Although the
adjusted odds ratios were reported in only one study, the use of
adjusted odds ratios instead of the crude odds ratios would not
have changed our assessment of the risk factors.
Female sex was associated with higher all-cause mortality (OR
1.75, 95% 1.27–2.44) (Figure 2, Table 1). We also found a non-
significant trend towards higher rates of pneumonia (OR 3.03,
95% CI 0.91–10.00), ICU admission (OR 3.70, 95% CI 0.33–
50.00), and need for ventilator support (OR 2.94, 95% CI 0.43–
20.00) in women. Because overlap in study populations was likely
across some studies for mortality and pneumonia outcomes, a
sensitivity analysis was conducted excluding studies with a
potential overlap. The findings were similar (Table 1).
We found no evidence that older age was a risk factor for more
severe outcomes when comparing .65 years of age to non-elderly
adults (OR for all-cause mortality 1.04, 95% CI 0.12–9.08).
Children ,18 years of age were at lower risk of developing
pneumonia (OR 0.16, 95% CI 0.03–0.86) when compared to
adult patients. There was a non-significant tendency towards lower
mortality rates (0.48, 95% CI 0.13–1.79) and lower risk of
pneumonia (OR 0.12, 95% CI 0.01–1.03) when compared to non-
elderly adults. We found that children of ,5 years of age were at
lower risk of death when compared to older children 5–18 years of
age (OR 0.44, 0.25–0.79; Figure 3) with a non-significant trend
towards a lower likelihood of developing pneumonia or need
ventilator support.
Only two studies reported on the presence of co-morbidities as
potential traditional risk factors. Although no significant differ-
ences were found, there was a non-significant tendency towards
increased risk of pneumonia in the presence of co-morbidities (OR
1.71, 95% CI 0.35–8.36). No significant differences in outcomes
were found for smoking.
The only comparison with significant heterogeneity was for all-
cause mortality when comparing paediatric patients to non-elderly
adults (I2 = 73%). A subgroup analysis excluding studies at highest
risk of bias (Newcastle-Ottawa scale of 3 or lower) reduced the I2
to 0% with a smaller overall effect (OR 0.90, 95% CI 0.51–1.57
versus OR 0.48, 95% CI 0.13–1.79) in the primary analysis.
Discussion
We found that female sex was associated with worse outcomes
following H5N1 infection and that children, particularly those ,5
years old, had better outcomes. Data on underlying co-morbidities
as risk factors for severe outcomes were scarce and therefore there
is no evidence demonstrating that co-morbidities affect the
outcome in patients infected with H5N1.
At the time of our literature search, 539 human cases with
H5N1 infections from 15 countries had been reported to WHO
[28]. In the 20 studies identified in our systematic review, a total of
999 cases were reported. While it seems unlikely that a large
number of confirmed H5N1 infections have not been reported to
WHO [29], the excess in cases in combination with identical time
periods and regions reported in included studies indicates overlap
in patient populations reported in the literature. In particular,
there was an overlap between two large WHO reports (Appendix
Figure 3. Forest plot comparing mortality in children less than 5 years of age to 5–18 years of age.
doi:10.1371/journal.pone.0089697.g003
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A, references 11 and 13) and studies published by local
investigators. In a sensitivity analysis we excluded studies that
appeared to have included some participants reported in another
included study, the results were in keeping with the primary
analyses. Since the overlap in participants between studies was
never 100%, the full dataset was presented as the primary analysis.
Female sex was associated with a higher mortality risk as well as
with a non-significant trend for other severe outcomes. Our
findings are in line with a report from Egypt where the H5N1 case
fatality rate was 49% in females compared to 8% in males [30]. Of
note, the overall mortality rate was lower in Egypt as compared to
mortality rates reported from other countries (34 versus 66%) [30].
A higher mortality in females was also found in a review of 294
cases occurring between 2006 and 2010 published by Fiebig et al.
[29]. Women infected with H5N1 were older [29] and most of the
affected women were housewives taking care of poultry [31]. In
contrast, the males were largely pre-school boys that got exposed
while playing outdoors [31]. An exposure to a greater inoculum is
one possibility for the worse outcomes in women. Another is that
the sex differences were confounded by age: females were likely
exposed at an older age than boys, and it was shown that younger
age, in particular ,5 years of age, was associated with a lower risk
for severe outcomes. This is in keeping with the findings in the
above mentioned study by Fiebig et al. There, the authors found
an even more pronounced difference with five to six times lower
odds for death for children up to 9 years of age as compared to a
number of other age groups [29].
In contrast to non-H5N1 influenza infections where older age
was shown to be a risk factor for severe outcomes for seasonal
influenza as well as during the 2009 H1N1 pandemic [3], this does
not seem to be true for H5N1 infections. One can hypothesize that
previous exposure to other subtypes may have offered protection
against H5N1 [32].
One limitations of this systematic review is the potential for
reporting bias. In particular asymptomatic patients or patients
with minor symptoms were likely underrepresented in the cases
reported. In fact, a 1 to 2% infection rate in those exposed was
found in serological studies which would result in much higher
number of cases than reported [33], which in turn is regarded to
be an overestimate by others [34]. Adjusted risk estimates also
were not available. Thus, modifying risk factors such as differing
time to oseltamivir treatment or the availability of health care may
have biased outcomes [29,35]. Also, we did not consider articles in
Chinese or other languages spoken in the regions where H5N1 is
endemic. However, we did not find any relevant articles on H5N1
when screening titles and abstracts of the 50 Chinese articles that
were excluded. Among the remaining 220 articles that were
excluded due to language, we only identified three review articles
on H5N1 when searching for the key words ‘‘avian’’ or ‘‘H5N1’’ in
the title. Thus, we believe that we did not miss any relevant articles
on Avian Influenza in the databases that we searched due to
restrictions on language. Finally, sample sizes for some rarely
reported risk factor-outcome comparisons were small explaining
the low precision and likely the lack of statistical significance for
some of these trends that we noted.
In summary, we found evidence that females were at increased
risk for complications following H5N1 infection while young age
protected against severe outcomes. Research on traditional risk
factors is scarce and is required.
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